



Melanoma Summit

New Zealand 2018

Programme

2-3 November 2018
Cordis Hotel, Auckland

Programme

Friday 2 November

Welcome

Room: The Great Room

0830 Welcome

0845 Opening address

Mr Andrew Connolly, Chair, Medical Council of New Zealand

0855 2018 New Zealand Melanoma Summit overview

Dr Chris Boberg, Chair, 2018 New Zealand Melanoma Summit Planning Committee and Co-Chair, MelNet

0905 A challenge to participants from a patient perspective

Leisa Renwick

Session 1: Epidemiology and primary prevention

Chair: Tane Cassidy, General Manager Communications and Capacity,
Health Promotion Agency

Room: The Great Room

0910 Global trends in melanoma incidence and mortality and emerging issues in primary prevention and risk assessment

Professor David Whiteman, Senior Scientist and Deputy Director, QIMR Berghofer Medical Research Institute, Queensland, Australia

0940 Trends in melanoma incidence and mortality, and risk assessment in New Zealand

Dr Mary Jane Sneyd, Senior Research Fellow and Deputy Director, Hugh Adam Cancer Epidemiology Unit, Dunedin School of Medicine, University of Otago

Kindly sponsored by the Health Promotion Agency

0955 Questions and discussion

1015 Morning tea

Pre-function Area

Session 2: Clinical diagnosis

Chair: Dr Chris Boberg, Co-Chair, MelNet

Room: The Great Room

1045 Artificial intelligence and advances in dermatoscopy and teledermatology

Associate Professor Cliff Rosendahl, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

1115 Nodular melanoma (an important issue for New Zealand)

Professor John Kelly, Consultant Dermatologist, Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia

1145 Diagnosis and changes in histological classification: 8th edition American Joint Committee on Cancer

Dr Michael Hitchcock, Dermatopathologist, Auckland Anatomic Pathology Services, Auckland District Health Board

1215 Questions and discussion

1230 Lunch

Pre-function Area

Session 3: Melanoma management

Chair: Mr Gary Duncan, Co-Chair, MelNet

Room: The Great Room

1315 The critical role of sentinel node biopsy in the management of melanoma

Professor John Thompson, Melanoma Institute Australia and Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia

1345 Melanoma Standards update

Dr Richard Martin, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board

1400 Questions and discussions

1415 Session 4: Concurrent breakout session 1

[4A] MelNet melanoma multi-disciplinary meeting: challenging cases 1

Chair: Dr Richard Harman, Clinical Director, Department of General Surgery and Endocrine, Breast and Melanoma Surgeon, North Shore Hospital

Room: Crystal I

In this session, a multi-disciplinary panel will discuss the clinical management of a range of challenging or unusual cases of melanoma. A similar session will be repeated in Breakout Session 5A with a different panel and cases.

Delegates are encouraged to attend only **one** of these sessions.

Panel:

- *Dr Mike McCrystal*, Medical Oncologist, Auckland
- *Dr Gareth Rivalland*, Medical Oncologist, Auckland
- *Professor John Thompson*, Melanoma Institute Australia and Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia
- *Mr Chris Adams*, Plastic and Reconstructive Surgeon, Hutt Valley District Health Board
- *Dr Maria Pearse*, Radiation Oncologist, Auckland Hospital
- *Dr Fiona Larsen*, Dermatologist, Fiona Larsen Dermatology, Auckland
- *Dr Franz Strydom*, GP with special interest in skin cancer, Skinspots Skin Cancer Clinic, Mt Maunganui

[4B] Dermatoscopy in action

Chair: Dr Chris Boberg, Co-Chair, MelNet

Room: Gallery 4

This session presented by Associate Professor Cliff Rosendahl will teach the basics of the 'chaos and clues' approach to dermatoscopy in diagnosing melanoma and will demonstrate its practical application to specific cases.

Presenter:

- **Associate Professor Cliff Rosendahl**, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

[4C] Sunscreens: Current issues and controversies

Chair: Megan Chapman, Manager Child and Family Health, Health Promotion Agency

Room: Crystal II

In this session Professor David Whiteman will provide an overview of molecular studies of sunscreen in humans. Belinda Castles (Senior Writer, Consumer NZ) will then discuss consumer concerns about sunscreen, including New Zealand's lack of regulations and the results of Consumer NZ's testing programme. This will be followed by a discussion on the implications of this information for New Zealanders.

Presenters:

- **Professor David Whiteman**, Senior Scientist and Deputy Director, QIMR Berghofer Medical Research Institute, Queensland, Australia
- **Belinda Castles**, Senior Writer, Consumer NZ

[4D] Melanoma Research and Therapy Special Interest Group: Translational and collaborative melanoma research in New Zealand

Co-chairs: Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services and Professor Mike Eccles, Professor, Department of Pathology, University of Otago

Room: Gallery 3

This session will discuss three translational and collaborative research projects relating to melanoma, and the implications this research may have on the way melanoma is managed and treated in future.

Presenters:

- **Dr Rosalie Stephens**, Medical Oncologist, Auckland District Health Board Oncology Services
A Randomised Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma
- **Professor Peter Shepherd**, Deputy Director Maurice Wilkins Centre
Combination therapy for melanoma
- **Professor Mike Eccles**, Professor, Department of Pathology, University of Otago
Epigenomic profiling to predict patient response to melanoma immunotherapy

1515 Afternoon tea

Pre-function Area

1545 Session 5: Concurrent breakout session 2

[5A] MelNet melanoma multi-disciplinary meeting: challenging cases 2

Chair: Dr Richard Harman, Clinical Director, Department of General Surgery and Endocrine, Breast and Melanoma Surgeon, North Shore Hospital

Room: Gallery 4

This session will focus on the clinical management of challenging or unusual cases of melanoma. A multi-disciplinary panel will discuss a range of cases. This will be a repeat of Breakout Session 4A but with a different panel and cases.

Delegates are encouraged to attend only **one** of these sessions.

Panel:

- **Dr Rosalie Stephens**, Medical Oncologist, Auckland District Health Board Oncology Services
- **Dr Susan Seifried**, General Surgeon, Nelson Marlborough District Health Board
- **Mr Jeremy Simcock**, Plastic Surgeon, Canterbury District Health Board
- **Dr Fergus Oliver**, Dermatologist, Dermatopathologist and Mohs Surgeon, Auckland Skin and Cancer Foundation
- **Dr Mark Foley**, Skin Cancer Doctor, The Skin Clinic Marlborough

[5B] Difficult cases at the clinical pathology interface

Chair: Dr Ben Tallon, Dermatologist SKIN Dermatology Institute Tauranga

Room: Crystal II

This panel session will explore the interface between histological and clinical diagnosis using a range of difficult cases such as dysplastic naevi, spitz tumours, and BAPomas as examples.

Panel:

- **Professor John Kelly**, Consultant Dermatologist, Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia
- **Associate Professor Cliff Rosendahl**, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia
- **Dr Michael Hitchcock**, Dermatopathologist, Auckland Anatomic Pathology Services, Auckland District Health Board
- **Dr Richard Massey**, Pathologist, Pathlab Bay of Plenty

[5C] Use of technologies and their potential role in prevention and diagnosis

Chair: Adrian Bowling, Chief Technology Officer, Molemap New Zealand

Room: Crystal I

This session will discuss the current impact of technology and its role in the future of prevention and early detection of melanoma.

Panel:

- **Dr Martin Haskett**, Consultant, MoleMap Australia
- **Maria Buckingham**, Group Training and Quality Manager, MoleMap Australia
- **Ming Cheuk**, Chief Technology Officer, Spark64
- **Hayden Laird**, Chief Executive, FirstCheck
- **Michel Nieuwoudt**, Senior Research Fellow, School of Chemical Sciences and Photon Factory, University of Auckland

[5D] Snapshots of clinical innovations

Chair: Dr Chris Boberg, Co-Chair, MelNet

Room: Gallery 3

Presenters whose submitted abstracts have been selected will provide snapshots clinical innovations.

Presenters:

- **Dr Richard Martin**, Surgical Oncologist New Zealand Melanoma Unit, Waitemata District Health Board
The use of sentinel node biopsy and novel molecular approaches to improve triage in high risk cutaneous SCC of the head and neck
- **Michael Sunderland**, Intern, Waitemata District Health Board
Tele dermatology and e-referral grading for melanoma, a successful model of care
- **Dr Rebecca Teague**, Surgical Registrar, Waitemata District Health Board
The virtual skin lesion clinic (VLC) – an evaluation of a new triage system for melanoma
- **Dr Keith Monnington**, President, Skin Cancer College Australasia and GP with special interest in skin cancer, Skinspots Skin Cancer Clinic, Mount Maunganui
Learning every day
- **Daniel Wen**, Medical Student, University of Auckland
Waitemata District Health Board Skin Service: GP surgeon scheme, an effective model of care

1645 Session 6: Day one breakout sessions – highlights and recommendations

Chair: Mr Gary Duncan, Co-Chair, MelNet

Room: The Great Room

1715 MelNet AGM

Crystal II

Presenters

- **Heather Knewstubb**, Health Promotion Advisor, Cancer Society of New Zealand National Office
Protecting our tamariki from UV Radiation
- **Dr Rebecca Bell**, Researcher, Health Promotion Agency
Barbara Hegan, Senior Advisor Skin Cancer Prevention, Health Promotion Agency
Communicating UVR risk to New Zealanders: exploring key knowledge gaps
- **Ryan Gage**, Assistant Research Fellow, University of Otago, Wellington
Recent sun safety observations in Aotearoa New Zealand: Implications for policy and research
- **Ryan Gage**, Assistant Research Fellow, University of Otago, Wellington
Strategies to strengthen skin cancer prevention in New Zealand: Views of key stakeholders
- **Bronwen McNoe**, Research Fellow Cancer Society Social and Behavioural Research Unit,
Department of Preventive and Social Medicine, University of Otago
Sunbeds and the second-hand market in New Zealand
- **Narelle Williams**, Senior Project Officer, Australia and New Zealand Melanoma Trials Group
Exercise behaviours and fatigue in patients receiving immunotherapy for advanced melanoma:
a cross-sectional survey
- **Ruth Nicholson**, Owner and Course Director, NZ Laser Training Ltd
Understanding Laser and IPL and the risk of accidental removal of malignancies – an industry
update
- **Dr Franz Strydom**, GP with special interest in skin cancer, Skinspots Skin Cancer Clinic,
Mt Maunganui
ABCD versus SCAN
- **Valeriya Nazarova**, Department of Biotherapy, N.N Blokhin Russian Cancer Research Centre,
Moscow
Genetic analysis of ocular melanoma
- **Sandra Fitzgerald**, PhD student, University of Auckland
Development of plasma genomic biomarkers for mutation detection and monitoring in New
Zealand cancer patients

1845 Conference dinner

Guest speaker

Room: The Great Room

Responsible hosting

The MelNet Executive Committee and the Health Promotion Agency are responsible hosts. Therefore food, water and non-alcoholic drinks will be offered at the poster session and conference dinner.

Saturday 3 November

0715 Session 7: Immunotherapy – the New Zealand story: a breakfast panel discussion

Co-Chairs: Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services and Mr Gary Duncan, Co-Chair, MelNet **Room:** The Great Room

To commence with a buffet breakfast, this session will analyse the impact of immunotherapies on melanoma treatment in New Zealand over the past two years. This will be supported by stories told by survivors of their experiences.

Presenters:

- **Dr Rosalie Stephens**, Medical Oncologist, Auckland District Health Board Oncology Services
- **Leisa Renwick**, Patient advocate
- **Shane Callaghan**, Patient

Proudly supported by MSD NZ LTD

Session 8: Advances in therapy and care

Chair: Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services **Room:** The Great Room

0830 Standard of care for stage IV metastatic melanoma and future prospects

Associate Professor Victoria Atkinson, Senior Staff Specialist Medical Oncologist, Princess Alexandra Hospital, Brisbane, Australia

0900 The nurse's role in supporting patients receiving immunotherapy

Dr Donna Milne, Melanoma Nurse Consultant and Clinical Nurse Researcher, Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria, Australia

0930 Questions and discussion

Session 9: Advances in melanoma research in New Zealand

Chair: Professor Mike Eccles, Professor, Department of Pathology, University of Otago **Room:** The Great Room

0945 New opportunities for personalised immunotherapy

Professor Rod Dunbar, Director, Maurice Wilkins Centre Auckland

0955 New combinations of drugs to treat melanoma

Professor Peter Shepherd, Deputy Director, Maurice Wilkins Centre Auckland

1005 Biomarkers of response to immune checkpoint inhibitors used to treat melanoma

Professor Mike Eccles, Professor, Department of Pathology, University of Otago

1015 Stage III melanoma – not as easy as it looks

Dr Richard North, Medical Oncologist, Bay of Plenty Cancer Centre

1025 Testing, testing....trials here and on the horizon

Dr Sanjeev Deva, Medical Director, Auckland Cancer Trials Centre and Medical Oncologist

1100 Session 10: Concurrent breakout session 3

[10A] GPs with a special interest in skin cancer**Chair:** Dr Chris Boberg, President, New Zealand Skin Cancer Doctors**Room:** Crystal I

Intended for those who are part of or interested in joining New Zealand Skin Cancer Doctors. The session will provide an overview of New Zealand Skin Cancer Doctors and the work they do. It will also include a discussion of interesting dermatoscopic and surgical cases. Attendees are encouraged to bring along cases to discuss.

[10B] NZ Skin Cancer Primary Prevention and Early Detection Strategy 2017 to 2022: health check on progress**Chair:** Megan Chapman, Manager Child and Family Health, Health Promotion Agency**Room:** Gallery 3

Intended for those working in primary prevention, this session will review primary prevention and early detection long term outcomes identified in the New Zealand Skin Cancer Primary Prevention and Early Detection Strategy 2017 to 2022. The session will conclude with a discussion on the 'When to apply sunscreen' – draft Position Statement resulting from the 2018 Brisbane Sunscreen Summit (as discussed in breakout 4C) and its potential incorporation into the Strategy.

[10C] The essential role of the nurse in melanoma care**Chair:** Trish Leathem, Skin Cancer Clinical Nurse Specialist, Middlemore Hospital, Counties Manukau District Health Board**Room:** Crystal II

Intended for nurses. This session will commence with a presentation from Dr Donna Milne, who through detailed case studies will address the essential role of nurse practitioners in the care of patients with melanoma. During the second half of the session, Katy Doherty (Dermatology Nurse and Skin Cancer Detection Care, Torbay Skin) will discuss the role of nurses in the early detection of skin cancer through dermatoscopy. There will be time for questions and discussion after each presentation.

Presenter:

- **Dr Donna Milne**, Melanoma Nurse Consultant and Clinical Nurse Researcher, Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria, Australia
- **Katy Doherty**, Dermatology Nurse and Skin Cancer Detection Care, Torbay Skin, Auckland

[10D] Research innovations

Chair: Mr Jeremy Simcock, Plastic Surgeon, Canterbury District Health Board

Room: Gallery 4

Presenters whose submitted abstracts have been selected will provide snapshots of innovative research projects.

Presenters:

- **Elizabeth Paton**, Chief Executive Officer, Australia and New Zealand Melanoma Trials Group
A randomised trial of excision margins for melanoma (ANZMTG 03.12 MelMarT)
- **Dr Ian Ong**, Surgical Registrar, North Shore Hospital
Quality assurance measures in axillary clearance for metastatic cutaneous melanoma
- **Tess Ostapowicz**, Research Nurse Malaghan Institute, Capital Coast District Health Board
The Melvac Study – a shared journey
- **Dr Catherine Barrow**, Medical Oncologist, Wellington Blood and Cancer Centre
Impact of checkpoint blockade immunotherapy (Pembrolizumab or Nivolumab) on vaccine-induced T cell responses
- **Narelle Williams**, Senior Project Officer, Australia and New Zealand Melanoma Trials Group
Australasian Merkel Cell Carcinoma Interest Group (AMIGOs) – improving the outlook for patients with Merkel cell carcinoma
- **Sandra Fitzgerald**, PhD student, University of Auckland
Development of plasma genomic biomarkers for mutation detection and monitoring in New Zealand cancer patients

1200 Session 11: Day two breakout sessions – highlights and recommendations

Chair: Mr Gary Duncan, Co-Chair, MelNet

Room: The Great Room

1215 Session 12: Managing stage III melanoma in the era of immune and targeted therapy

Chair: Dr Richard Martin, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board

Room: The Great Room

Professor John Thompson, Melanoma Institute Australia and Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia

The role of the surgical oncologist in managing advanced stage III melanoma in the era of immune and targeted therapy

Associate Professor Victoria Atkinson, Senior Staff Specialist Medical Oncologist, Princess Alexandra Hospital, Brisbane, Australia

Neoadjuvant and adjuvant management of stage III melanoma – best practice in 2018

1250 Lunch

Pre-function Area

Session 13: Looking to the future of melanoma – moving the goalposts

Co-chairs: Trish Leatham, Skin Cancer Clinical Nurse Specialist, Middlemore Hospital, Counties Manukau District Health Board and Mr Gary Duncan, Co-Chair, MelNet **Room:** The Great Room

1330 New Zealand's quest for excellence in the delivery of melanoma care

Dr Chris Jackson, Medical Director, Cancer Society of New Zealand

1340 Panel: The future of melanoma prevention, diagnosis, treatment, care and research

Associate Professor Cliff Rosendahl, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

Associate Professor Victoria Atkinson, Senior Staff Medical Oncologist, Princess Alexandra Hospital Brisbane, Australia

Dr Chris Jackson, Medical Director, Cancer Society of New Zealand

Dr Donna Milne, Melanoma Nurse Consultant and Clinical Nurse Researcher, Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria, Australia

Dr Rosalie Stephens, Medical Oncologist, Auckland District Health Board Oncology Services

Leisa Renwick, Patient advocate

Professor David Whiteman, Senior Scientist and Deputy Director, QIMR Berghofer Medical Research Institute, Queensland, Australia

Professor John Thompson, Professor of Melanoma and Surgical Oncology, The University of Sydney, Australia

1415 Wrap up and recommendations

Mr Gary Duncan, Co-Chair, MelNet

1445 Closing remarks

Mr Gary Duncan and *Dr Chris Boberg*, Co-Chairs, MelNet

1500 Close

1515 Melanoma Research and Therapy Special Interest Group: Cancer Hub Platform

Chair: Professor Mike Eccles, Professor, Department of Pathology, University of Otago **Room:** Crystal II

The Melanoma Research and Therapy Special Interest Group is a national and inclusive multi-disciplinary group of melanoma health professionals and researchers seeking to achieve consensus on current issues, implement solutions to these issues and improve upon current standards of care by promoting and facilitating research in melanoma.

Following the conclusion of the 2018 New Zealand Melanoma Summit, a one-hour meeting of the Melanoma Research and Therapy Special Interest Group will be held to discuss the development of a Cancer Hub Platform. The purpose of this platform is to store and share research data and next generation sequencing data produced from the tissue of cancer patients, facilitating greater networking and collaboration between cancer researchers in New Zealand.

All health professionals and researchers with a special interest in melanoma research and therapy are invited to this MelNet-sponsored meeting.